Literature DB >> 23872863

Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.

K Kinugawa1, T Imamura, I Komuro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23872863     DOI： 10.1038/clpt.2013.147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

1.  Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.

Authors:  Shunta Akutsu; Yasuaki Mino; Takafumi Naito; Kohei Hoshikawa; Masao Saotome; Yuichiro Maekawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2022-05-23       Impact factor: 3.064

2.  Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.

Authors:  Keisuke Kida; Yugo Shibagaki; Naoto Tominaga; Naoki Matsumoto; Yoshihiro J Akashi; Fumihiko Miyake; Kenjiro Kimura
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 3.  Current and future G protein-coupled receptor signaling targets for heart failure therapy.

Authors:  Ashley Siryk-Bathgate; Samalia Dabul; Anastasios Lymperopoulos
Journal:  Drug Des Devel Ther       Date:  2013-10-11       Impact factor: 4.162

Review 4.  Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.

Authors:  Teruhiko Imamura; Koichiro Kinugawa
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

5.  Comparison of the Effects of Carperitide and Tolvaptan on Patients with Left Ventricular Dysfunction: A Two-Center Retrospective Study.

Authors:  Chikahiko Koeda; Shohei Yamaya; Maiko Hozawa; Masayuki Sato; Kazuhiro Nasu; Tomohiro Takahashi; Katsutoshi Terui
Journal:  Cardiol Res Pract       Date:  2017-07-12       Impact factor: 1.866

6.  Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study.

Authors:  Masami Nishino; Yasuyuki Egami; Akihiro Tanaka; Shodai Kawanami; Hiroki Sugae; Kohei Ukita; Akito Kawamura; Hitoshi Nakamura; Yutaka Matsuhiro; Koji Yasumoto; Masaki Tsuda; Naotaka Okamoto; Yasuharu Matsunaga-Lee; Masamichi Yano; Jun Tanouchi
Journal:  J Clin Med       Date:  2022-02-13       Impact factor: 4.241

7.  Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan.

Authors:  Takashi Kuragaichi; Yukihito Sato
Journal:  ESC Heart Fail       Date:  2020-11-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.